Trial Profile
To evaluate the effects of Eculizumab in patients with secondary atypical haemolytic uraemic syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- 03 Apr 2017 New trial record
- 20 Feb 2017 Results published in the Nephrology Dialysis Transplantation